China Biotech Licensing Opportunities 2026: Assets, Rights and Rules

The 2026 Opportunity in Numbers

Different providers measure China’s role in different ways — pipeline share, trial starts, deal value — but they point in the same direction.

Where the Licensable Assets Are

Oncology still leads, but 2026 deals show buyers paying for Chinese assets well beyond cancer. The table shows the therapeutic areas in our log and how the rights were split in each.

T-cell engagers and multispecific antibodies

Multispecific antibodies and T-cell engagers drew some of 2026’s largest upfronts and are moving into autoimmune disease. AbbVie took an option on Zelgen’s DLL3 trispecific T-cell engager and paid $650 million upfront for RemeGen’s PD-1/VEGF bispecific; Roche licensed Simcere Zaiming’s CD79a/CD19/CD3 trispecific. On the autoimmune side, UCB licensed Antengene’s CD19×CD3 engager and Novartis paid $575 million upfront for Abogen’s mRNA-encoded CD19×CD3 engager and options on further RNA programs.

ADCs and other conjugates

Antibody–drug conjugates remain a core China strength. Roche committed $570 million upfront and near-term for MediLink’s B7-H3 ADC YL201, already in Phase 3 in China, and in October licensed a portfolio of Hansoh ADCs for $400 million upfront and a potential total above $15 billion. Genentech licensed ADCs built on DualityBio’s DUPAC payloads, Pathos AI took Alphamab’s TROP2×HER3 bispecific ADC and GSK licensed HUTCHMED’s KRAS-EGFR antibody-targeted therapy conjugate. See our ADC licensing guide for the modality in depth.

Obesity, cardiometabolic and RNAi

The year’s largest China deal was metabolic: AstraZeneca paid $1.2 billion upfront for eight CSPC obesity and type 2 diabetes programs, with a potential total of $18.5 billion. Novo Nordisk licensed Hengrui’s oral GLP-1/GIP dual agonist HRS-1596 for $300 million upfront. RNA interference is a distinct trend: Madrigal licensed six preclinical Ribo siRNA programs for MASH, GSK took siRNAs from Frontier Biotech and SiranBio, AstraZeneca optioned two CSPC siRNAs for kidney disease and Roche licensed Rona’s ALK7 RNAi for obesity. Our obesity licensing guide covers the wider market.

Immunology and inflammation

Oral and long-acting immunology assets drew Western biotechs as well as big pharma: Avere licensed Hansoh’s oral IL-23 receptor antagonist for $120 million upfront, Spero took Innovent’s anti-CD40L antibody, and Sentivera, a new company founded by ARCH Venture Partners and Population Health Partners, licensed a preclinical Haisco program for type 2 inflammation.

Discovery and platform collaborations

A growing share of value sits in deals for programs that do not exist yet. Bristol Myers Squibb’s agreement with Hengrui covers 13 programs; Pfizer’s with Innovent covers 12. Eli Lilly signed discovery collaborations with Innovent, Insilico, Haisco, Abbisko and InnoCare in 2026. These deals buy a Chinese company’s discovery speed rather than a single molecule, and are usually priced with small upfronts and large contingent payments.

Worldwide vs Ex-China (ROW) Rights: How 2026 Deals Split Territory

Every China licence answers one question first: does the Chinese company keep its home market? In an ex-China (or ex-Greater China) deal, the buyer gets the rest of the world — the ROW rights — and the licensor keeps developing and selling the drug in China. In a worldwide licence, the buyer takes China too. Greater China normally means mainland China, Hong Kong, Macau and Taiwan, but the agreement’s own definition is what counts.

Medians use deals that disclosed the figure. “Clinical at signing” counts assets already in trials or approved when the deal was announced.

What the split shows:

• Clinical assets stay ex-China. 11 of 18 ex-China licences covered a drug already in trials; only 2 of 14 worldwide licences did (Sino Biopharm and Dizal Pharmaceutical). A licensor with Chinese clinical data and a domestic approval path has the most reason to keep China.
• Ex-China deals carried larger upfronts. The median disclosed upfront was $163M for ex-China licences against $90M for worldwide ones, consistent with their later stage.
• Taiwan is not automatic. In 3 ex-China deals the licensor kept only mainland China, Hong Kong and Macau, so Taiwan went to the buyer.
• Some licensors keep more of Asia. In 2 deals the licensor also kept other Asian markets, such as parts of East and Southeast Asia or India.
• Portfolio deals mix both. In 3 deals the rights differ by program — Pfizer, for example, takes global rights to four of Innovent’s 12 programs and ex-Greater China rights to four more.

Across all 34 deals that disclosed both an upfront and a total, upfront cash was 5.9% of headline value. Most of what a China licence is “worth” is contingent on milestones that may never be paid.

Territory, Deal by Deal

Buyer ← Chinese licensor, newest first. “Licensor keeps” follows each announcement’s wording; the licensor name links to the source. Verified through 19 Oct 2026.

Negotiating an Ex-China Licence: The Clauses That Matter

Splitting a drug between two owners creates issues a worldwide licence avoids. In our work on both sides of these deals, these are the terms that need the most attention:

1. Territory definition. Name every jurisdiction. Taiwan, and in some deals other Asian markets, go one way or the other depending on the drafting.
2. Data and right of reference. The buyer needs access to the licensor’s Chinese clinical and CMC data, and the right to reference it in FDA and EMA filings; the licensor needs the buyer’s global data for its NMPA filings.
3. Global trial coordination. Agree who runs multiregional trials, how Chinese sites participate and who pays — especially for pivotal studies the FDA will rely on.
4. Manufacturing and supply. Decide whether the licensor supplies, or the process transfers to a manufacturer outside China.
5. China options. Some buyers secure a way back into China: AstraZeneca can opt in to co-commercialise CSPC’s obesity programs there once approved.
6. Reciprocity. Bristol Myers Squibb’s deal with Hengrui runs both ways — Hengrui takes rights to BMS-originated assets in mainland China, Hong Kong and Macau.

Options (AbbVie–Zelgen, AstraZeneca–CSPC’s siRNA programs, Novartis–Abogen) and NewCo structures are covered in our outbound tracker; term sheet language is in our cross-border term sheet guide.

NMPA Rules That Shape a Licence

China’s regulator joined the International Council for Harmonisation (ICH) in 2017 and has since cut its review times. For a licensee, the rules below decide how quickly the licensor can generate data in China and how fast the drug can reach the Chinese market. All timelines are in working days.

China data and the FDA

Fast, inexpensive early-stage work is one of China’s main attractions. As we told Swissinfo in September 2026, “more Western biotechs are considering doing trials in China because they can get early-stage data for much less money.” Registrational data is different. In February 2022 the FDA’s oncology advisory committee voted 14–1 against relying on ORIENT-11, a Phase 3 trial of sintilimab run only in China, and the FDA’s complete response letter asked for a multiregional trial. Licensees should budget for global pivotal studies; our China clinical trials guide covers MRCT design, and our NMPA approval guide the full regulatory process.

Human Genetic Resources and Data Transfer

China’s human genetic resources (HGR) rules are the most deal-specific regulatory issue in a China licence. They are now administered by the National Health Commission, which took over from the Ministry of Science and Technology on 1 May 2024. Under the current framework:

• Foreign parties cannot collect or store Chinese HGR on their own and must work through a Chinese partner.
• Patents arising from international collaborations that use Chinese HGR must be filed jointly and are co-owned (Article 24 of the HGR Regulations). A licence can handle this with an exclusive grant-back of the Chinese party’s share and a narrow definition of the IP that falls under the rule.
• Exporting HGR materials needs prior approval; providing HGR information to a foreign party needs a filing.
• Clinical data is also personal information. Transfers abroad of sensitive personal information on 10,000 or more people in a year trigger a Cyberspace Administration security assessment, which can take several months.

China Market Access: NRDL, Commercial Insurance and VBP

China’s payer system matters to a licensee whenever the deal includes China — a worldwide licence, a co-commercialisation option, or royalties and milestones tied to the licensor’s Chinese sales.

For a novel licensed asset, the practical questions are when the NRDL negotiation will happen, who leads it, and whether the drug is a candidate for the commercial insurance list instead. VBP becomes relevant only once the molecule loses exclusivity in China.

Our 2026 Risk Assessment

How we rate the main China-specific risks for a licensee today, based on the rules above and our deal work.

The BIOSECURE provisions became law in December 2025 in the FY2026 National Defense Authorization Act; our BIOSECURE analysis covers the timeline and who is affected.

Conclusion

The China opportunity in 2026 is broad — multispecifics, ADCs, obesity, RNAi and immunology — and it is early: most assets are licensed before or around Phase 1, with upfronts a small share of headline value. The territory split is the first structural choice, and the data shows a pattern: Chinese companies keep their home market when they have clinical assets and a domestic path, and grant worldwide rights more readily for early programs. Buyers who define the territory precisely, secure data and supply rights, and plan for multiregional pivotal trials get the most from a China licence. Our in-licensing and out-licensing teams work on both sides of these deals.

Frequently Asked Questions

Methodology & Sources

The deal analysis covers licensing, collaboration and option deals announced between 1 January and 19 Oct 2026 in which a company domiciled in mainland China or Hong Kong grants rights outside Greater China, with a disclosed total of $1 billion or more or an upfront of $100 million or more. The licensed territory and the rights kept by the licensor were taken from each announcement. “Clinical at signing” means the lead asset was in clinical trials or approved when the deal was announced. Medians and the upfront share use only deals that disclosed the relevant figures. Regulatory rules are taken from the NMPA’s published texts; market figures come from the providers named and are not combined.

Sources:

1. Vision Lifesciences research: our own deal tracking and insights from our day-to-day cross-border licensing and M&A advisory work (about us)
2. Swissinfo, The numbers behind China’s pharma rise (3 Sep 2026; Citeline, GlobalData and Georgetown University data)
3. Reuters Breakingviews, China biotech’s ingenuity extends to dealmaking (16 Oct 2026; PharmCube data)
4. J.P. Morgan, Q3 2026 Biopharma Licensing and Venture Report (DealForma data)
5. NMPA, Provisions for Drug Registration, Article 23 (clinical trial review)
6. NMPA, Provisions for Drug Registration, Chapter IV (breakthrough therapy, conditional approval, priority review)
7. NMPA, Announcement on Optimizing the Review and Approval of Clinical Trials of Innovative Drugs ([2025] No. 86)
8. Healio, FDA rejects sintilimab with chemotherapy for non-small cell lung cancer (24 Mar 2022)
9. Morgan Lewis, Strategic Compliance: Navigating HGR and Data Risks in China Life Sciences Transactions (May 2026)
10. Covington, China’s NHC issues updated guidelines on human genetic resources management (Apr 2025)
11. CMS, China has renewed the NRDL and released the first commercial reimbursement list for innovative drugs
12. Caixin Global, China eases drug procurement rules, keeps winning bids secret (29 Oct 2025)